ReP USP - Resultado da busca

Artigo de periodico
The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study (2015)
Curtivo, Cátia Panizzon Dal; Funghi, Nathália Bitencourt; Tavares, Guilherme Diniz; Barbosa, Sávio Fujita; Löbenberg, Raimar; Bou-Chacra, Nadia Araci
Fonte: Pharmaceutical Development and Technology. Unidade: FCF
Assuntos: ESPECTROSCOPIA INFRAVERMELHA, ANÁLISE MULTIVARIADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CURTIVO, Cátia Panizzon Dal et al. The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study. Pharmaceutical Development and Technology, v. 20, n. 3, p. 345-351, 2015Tradução . . Disponível em: https://doi.org/10.3109/10837450.2013.867448. Acesso em: 28 nov. 2025.
APA
Curtivo, C. P. D., Funghi, N. B., Tavares, G. D., Barbosa, S. F., Löbenberg, R., & Bou-Chacra, N. A. (2015). The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study. Pharmaceutical Development and Technology, 20( 3), 345-351. doi:10.3109/10837450.2013.867448
NLM
Curtivo CPD, Funghi NB, Tavares GD, Barbosa SF, Löbenberg R, Bou-Chacra NA. The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study [Internet]. Pharmaceutical Development and Technology. 2015 ; 20( 3): 345-351.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2013.867448
Vancouver
Curtivo CPD, Funghi NB, Tavares GD, Barbosa SF, Löbenberg R, Bou-Chacra NA. The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study [Internet]. Pharmaceutical Development and Technology. 2015 ; 20( 3): 345-351.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2013.867448
Artigo de periodico
Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer (2015)
Barbosa, Sávio Fujita; Takatsuka, Takayuki; Tavares, Guilherme Diniz; Araujo, Gabriel Lima Barros de ; Wang, Hui; Vehring, Reinhard; Löbenberg, Raimar; Bou-Chacra, Nadia Araci
Fonte: Pharmaceutical Development and Technology. Unidade: FCF
Assuntos: NANOPARTÍCULAS, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARBOSA, Sávio Fujita et al. Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer. Pharmaceutical Development and Technology, 2015Tradução . . Disponível em: https://doi.org/10.3109/10837450.2015.1063650. Acesso em: 28 nov. 2025.
APA
Barbosa, S. F., Takatsuka, T., Tavares, G. D., Araujo, G. L. B. de, Wang, H., Vehring, R., et al. (2015). Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer. Pharmaceutical Development and Technology. doi:10.3109/10837450.2015.1063650
NLM
Barbosa SF, Takatsuka T, Tavares GD, Araujo GLB de, Wang H, Vehring R, Löbenberg R, Bou-Chacra NA. Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer [Internet]. Pharmaceutical Development and Technology. 2015 ;[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2015.1063650
Vancouver
Barbosa SF, Takatsuka T, Tavares GD, Araujo GLB de, Wang H, Vehring R, Löbenberg R, Bou-Chacra NA. Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer [Internet]. Pharmaceutical Development and Technology. 2015 ;[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2015.1063650
Artigo de periodico
Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention (2015)
Pinheiro, Vanessa Alves; Serikaku, Daniela; Baby, André Rolim ; Velasco, Maria Valéria Robles ; Kaneko, Telma Mary ; Consiglieri, Vladi Olga
Fonte: Pharmaceutical Development and Technology. Unidade: FCF
Assunto: ANTIFÚNGICOS (TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINHEIRO, Vanessa Alves et al. Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention. Pharmaceutical Development and Technology, v. 20, n. 2, p. 197-203, 2015Tradução . . Disponível em: https://doi.org/10.3109/10837450.2013.860544. Acesso em: 28 nov. 2025.
APA
Pinheiro, V. A., Serikaku, D., Baby, A. R., Velasco, M. V. R., Kaneko, T. M., & Consiglieri, V. O. (2015). Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention. Pharmaceutical Development and Technology, 20( 2), 197-203. doi:10.3109/10837450.2013.860544
NLM
Pinheiro VA, Serikaku D, Baby AR, Velasco MVR, Kaneko TM, Consiglieri VO. Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention [Internet]. Pharmaceutical Development and Technology. 2015 ; 20( 2): 197-203.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2013.860544
Vancouver
Pinheiro VA, Serikaku D, Baby AR, Velasco MVR, Kaneko TM, Consiglieri VO. Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention [Internet]. Pharmaceutical Development and Technology. 2015 ; 20( 2): 197-203.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2013.860544
Artigo de periodico
Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design (2013)
Duque, Marcelo Dutra; Kreidel, Rogério Nepomuceno; Taqueda, Maria Elena Santos ; Baby, André Rolim ; Kaneko, Telma Mary ; Velasco, Maria Valéria Robles ; Consiglieri, Vladi Olga
Fonte: Pharmaceutical Development and Technology. Unidades: EP, FCF
Assuntos: COMPRIMIDOS, CELULOSE, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DUQUE, Marcelo Dutra et al. Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design. Pharmaceutical Development and Technology, v. 18, n. 5, p. 1247-1254, 2013Tradução . . Disponível em: https://doi.org/10.3109/10837450.2012.693508. Acesso em: 28 nov. 2025.
APA
Duque, M. D., Kreidel, R. N., Taqueda, M. E. S., Baby, A. R., Kaneko, T. M., Velasco, M. V. R., & Consiglieri, V. O. (2013). Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design. Pharmaceutical Development and Technology, 18( 5), 1247-1254. doi:10.3109/10837450.2012.693508
NLM
Duque MD, Kreidel RN, Taqueda MES, Baby AR, Kaneko TM, Velasco MVR, Consiglieri VO. Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design [Internet]. Pharmaceutical Development and Technology. 2013 ; 18( 5): 1247-1254.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2012.693508
Vancouver
Duque MD, Kreidel RN, Taqueda MES, Baby AR, Kaneko TM, Velasco MVR, Consiglieri VO. Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design [Internet]. Pharmaceutical Development and Technology. 2013 ; 18( 5): 1247-1254.[citado 2025 nov. 28 ] Available from: https://doi.org/10.3109/10837450.2012.693508

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos